公开(公告)号：US10065982B2

公开(公告)日：2018-09-04

申请号：US14382480

申请日：2013-03-01

Applicant: Saraya Co., Ltd.

Inventor： Yoshihiko Hirata ,  Mizuyuki Ryu ,  Hitoshi Ito ,  Michiaki Araki

IPC: C07H15/10 ,  C07H15/04 ,  A61Q19/00 ,  A61K8/60 ,  A23L29/10 ,  A23L33/12

Abstract: The present invention provides a high-purity acid-form sophorolipid (SL)-containing composition characterized by substantially not containing acetic acid. The high-purity acid-form SL-containing composition can be produced, for example, by the following method: (i) adjusting the pH of a partially purified acid-form SL-containing composition to an acidic range; and (ii-a) subjecting an acidified partially purified acid-form SL-containing composition obtained in step (i) to chromatography to acquire a fraction containing an acid-form SL, or (ii-b) leaving the acidified partially purified acid-form SL-containing composition obtained in step (i) to stand under a low-temperature condition to acquire a resulting gelled object.

公开(公告)号：US20150112049A1

公开(公告)日：2015-04-23

申请号：US14382480

申请日：2013-03-01

Applicant: Saraya Co., Ltd.

Inventor： Yoshihiko Hirata ,  Mizuyuki Ryu ,  Hitoshi Ito ,  Michiaki Araki

IPC: C07H15/10

CPC classification number: C07H15/10 ,  A23L29/10 ,  A23L33/12 ,  A61K8/602 ,  A61K2800/10 ,  A61Q19/00 ,  C07H15/04

Abstract: The present invention provides a high-purity acid-form sophorolipid (SL)-containing composition characterized by substantially not containing acetic acid. The high-purity acid-form SL-containing composition can be produced, for example, by the following method: (i) adjusting the pH of a partially purified acid-form SL-containing composition to an acidic range; and (ii-a) subjecting an acidified partially purified acid-form SL-containing composition obtained in step (i) to chromatography to acquire a fraction containing an acid-form SL, or (ii-b) leaving the acidified partially purified acid-form SL-containing composition obtained in step (i) to stand under a low-temperature condition to acquire a resulting gelled object.

Abstract translation: 本发明提供了一种含有基本上不含乙酸的高纯度酸形式的含有喔疮脂（SL）的组合物。 高纯度酸形式的含SL的组合物可以通过例如以下方法制备：（i）将部分纯化的含酸型SL的组合物的pH调节至酸性范围; 和（ii-a）将步骤（i）中获得的酸化的部分纯化的含酸形式的含SL的组合物进行色谱以获得含有酸型SL的级分，或（ii-b）将酸化的部分纯化的酸 - 将步骤（i）中获得的含SL的组合物置于低温条件下以获得所得胶凝物。

公开(公告)号：US20170014489A1

公开(公告)日：2017-01-19

申请号：US15124432

申请日：2015-03-10

Applicant: SARAYA CO., LTD.

Inventor： Yasushi Suzuki ,  Hiromitsu Tabata ,  Mizuyuki Ryu ,  Nanase Ishii ,  Takashi Takeuchi ,  Yasuki Matsumura ,  Kentaro Matsumiya

IPC: A61K38/40 ,  A61K47/44 ,  A61K47/26 ,  A23L9/10 ,  A61K47/06 ,  A61K9/107 ,  A23L33/115 ,  A23G1/36 ,  A61K9/00 ,  A61K45/06

CPC classification number: A61K38/40 ,  A23G1/36 ,  A23L9/12 ,  A23L33/115 ,  A23V2002/00 ,  A61K9/0053 ,  A61K9/107 ,  A61K45/06 ,  A61K47/06 ,  A61K47/26 ,  A61K47/44

Abstract: The present invention provides an orally administered composition comprising a sophorolipid, a physiologically active substance, and an oil or fat, wherein the physiologically active substance exhibits an improved bioavailability.

Abstract translation: 本发明提供了包含槐糖脂，生理活性物质和油或脂肪的口服给药组合物，其中所述生理活性物质表现出改善的生物利用度。

公开(公告)号：US20220272963A1

公开(公告)日：2022-09-01

申请号：US17664194

申请日：2022-05-19

Applicant: Saraya Co., Ltd. ,  Osaka University

Inventor： Asuka Nogami ,  Motoki Tatsumi ,  Nanase Ishii ,  Mizuyuki Ryu ,  Yoshihiko Hirata ,  Yoshiki Sawa ,  Shigeru Miyagawa ,  Atsuhiro Saito ,  Hirotatsu Ohkawara

IPC: A01N1/02 ,  C12N1/04 ,  C12N5/0775

Abstract: A cell cryopreservation method including adding a 1 volume % of a composition comprising 0.01 wt % to 20 wt % of a sophorose lipid to cells in a cell culture medium just before or up to 6 hours before cryopreserving the cells; and cryopreserving the cell culture medium, wherein the composition improves cell viability after cryopreservation compared to cells that are cryopreserved with a similar composition that does not contain the sophorose lipid.

公开(公告)号：US20200045955A1

公开(公告)日：2020-02-13

申请号：US16482236

申请日：2018-01-30

Applicant: Saraya Co., Ltd. ,  Osaka University

Inventor： Asuka Nogami ,  Motoki Tatsumi ,  Nanase Ishii ,  Mizuyuki Ryu ,  Yoshihiko Hirata ,  Yoshiki Sawa ,  Shigeru Miyagawa ,  Atsuhiro Saito ,  Hirotatsu Ohkawara

IPC: A01N1/02 ,  C12N1/04 ,  C12N5/0775

Abstract: This composition can be easily added when cryopreserving cells and improves cell viability. 1 volume % of the composition containing 0.01 wt % to 20 wt % of a sophorose lipid is added just before or up to 6 hours before cryopreservation and cells are stored. This composition can improve cryopreservation cell viability as it reduces freezing damage to cells. With this composition, cells can be stored without using DMSO and blood serum. This is a simple and inexpensive storage method as it does not require fine control of the freezing rate during cell cryopreservation.

公开(公告)号：US12127553B2

公开(公告)日：2024-10-29

申请号：US17664194

申请日：2022-05-19

Applicant: Saraya Co., Ltd. ,  Osaka University

Inventor： Asuka Nogami ,  Motoki Tatsumi ,  Nanase Ishii ,  Mizuyuki Ryu ,  Yoshihiko Hirata ,  Yoshiki Sawa ,  Shigeru Miyagawa ,  Atsuhiro Saito ,  Hirotatsu Ohkawara

IPC: C12N1/04 ,  A01N1/02 ,  C12N5/0775

CPC classification number: A01N1/0221 ,  C12N1/04 ,  C12N5/0663 ,  C12N5/0665

Abstract: A cell cryopreservation method including adding a 1 volume % of a composition comprising 0.01 wt % to 20 wt % of a sophorose lipid to cells in a cell culture medium just before or up to 6 hours before cryopreserving the cells; and cryopreserving the cell culture medium, wherein the composition improves cell viability after cryopreservation compared to cells that are cryopreserved with a similar composition that does not contain the sophorose lipid.

公开(公告)号：US10307466B2

公开(公告)日：2019-06-04

申请号：US15124432

申请日：2015-03-10

Applicant: SARAYA CO., LTD.

Inventor： Yasushi Suzuki ,  Hiromitsu Tabata ,  Mizuyuki Ryu ,  Nanase Ishii ,  Takashi Takeuchi ,  Yasuki Matsumura ,  Kentaro Matsumiya

IPC: A61K31/7012 ,  A61K38/40 ,  A61K45/06 ,  A23L33/115 ,  A23L9/10 ,  A23G1/36 ,  A61K9/00 ,  A61K9/107 ,  A61K47/06 ,  A61K47/26 ,  A61K47/44

Abstract: The present invention provides an orally administered composition comprising a sophorolipid, a physiologically active substance, and an oil or fat, wherein the physiologically active substance exhibits an improved bioavailability.